Top Markets
Coin of the day
CTI BioPharma Corp. CTI BioPharma Corp.

CTI BioPharma Corp.

CTIC
Classement en actions #12604
CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery,... CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key product is VONJO (pacritinib), an oral kinase inhibitor currently under investigation, specifically designed to target JAK2, FLT3, IRAK1, and CSF1R for the management of adult patients with myelofibrosis. The company holds licensing and collaboration agreements with Teva Pharmaceutical Industries Ltd., SBIO Pte Ltd., and Baxalta. Established in 1991 and based in Seattle, Washington, CTI BioPharma Corp. was previously known as Cell Therapeutics, Inc., adopting its current name in May 2014.
Prix de l'action
$9.09
Dernière synchronisation: 2023-06-23
Capitalisation boursière
$567.77M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange CTI BioPharma Corp. (CTIC)

Catégorie

Ratio P/B pour CTI BioPharma Corp. (CTIC)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de CTI BioPharma Corp., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour CTI BioPharma Corp. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH